For sufferers with kind 2 diabetes (T2D) and continual obstructive pulmonary dysfunction (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are related to a decreased danger for reasonable or extreme COPD exacerbations in contrast with dipeptidyl peptidase 4 inhibitors (DPP-4is), in accordance with a research revealed on-line Feb. 10 in JAMA Inner Medication.
Avik Ray, M.D., from Brigham and Girls’s Hospital and Harvard Medical College in Boston, and colleagues performed a comparative effectiveness research to evaluate the danger for reasonable or extreme COPD exacerbations amongst sufferers aged 40 years or older with T2D and energetic COPD who initiated therapy with SGLT-2is versus DPP-4is; GLP-1 RAs versus DPP-4is; and SGLT-2is versus GLP-1 RAs (27,991; 32,107; and 36,218 pairs, respectively).
The researchers discovered that the danger for reasonable or extreme COPD exacerbation was decrease amongst these handled with SGLT-2is versus DPP-4is and amongst these handled with GLP-1 RAs versus DPP-4is (9.26 versus 11.4 per 100 person-years [hazard ratio, 0.81] and 9.89 versus 11.49 per 100 person-years [hazard ratio, 0.86], respectively), with minimal variations noticed amongst these handled with SGLT-2is versus GLP-1 RAs. Throughout sensitivity and subgroup analyses, the outcomes have been constant.
“These findings suggest that SGLT-2is and GLP-1 RAs may be preferable to DPP4is when deciding among glucose-lowering medications for patients with T2D and active COPD,” the authors write. “However, given the observational nature of the study, there is potential for residual or unmeasured confounding, and findings from similar clinical studies and clinical trials will help corroborate these results.”
A number of authors disclosed ties to the pharmaceutical trade; one writer disclosed being an skilled witness in litigation towards inhaler producers.
Extra info:
Avik Ray et al, Glucose-Reducing Medicines and Threat of Continual Obstructive Pulmonary Illness Exacerbations in Sufferers With Kind 2 Diabetes, JAMA Inner Medication (2025). DOI: 10.1001/jamainternmed.2024.7811
Nathan M. Stall et al, Pleotropic Results of Glucose-Reducing Medicines—Want for Cautious Interpretation of Goal Trial Emulation Research, JAMA Inner Medication (2025). DOI: 10.1001/jamainternmed.2024.7812
© 2025 HealthDay. All rights reserved.
Quotation:
Sure glucose-lowering meds related to decrease danger for COPD exacerbations (2025, February 21)
retrieved 21 February 2025
from https://medicalxpress.com/information/2025-02-glucose-lowering-meds-copd-exacerbations.html
This doc is topic to copyright. Aside from any truthful dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
